Ryvu Therapeutics S.A.

zł 16.44As of Sun 8 Nov 2026, 12:00 UTC
WSE:RVUHealthcare
Country Poland
PE (Fwd) •••
TSR 10Y CAGR (0.78%)
Div yield —
ROE (39.51%)
Biotechnology
Beta (5Y) 0.36
PE TTM —
TSR TTM (30.92%)
Mkt cap zł 380.1M
ROIC (142.75%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
zł 20
18.97%
(60.47%)
Hold 8|9|4|0|2
4Q25
1Q26
2Q26
3Q26
Earnings per sharezł
0.32
0.35
0.36
0.37
26.19%
28.48%
27.46%
22.18%
Revenuezł M
16.91
16.61
17.01
16.70
4.46%
1.27%
5.27%
(2.35%)
Peers (US$95.99M)
Cap (US$)
PE
96.40M
—
75.03M
—
Capital
TTM
5Y
10Y
Leveragex
0.712
(0.273)
(0.175)
EBIT/Intx
0.488
0.292
0.297
Own earn%
(145.73)
21.05
7.96
Sh yield%
34.54
28.92
28.92
Owners
Insiders/Inst%
9.38
64.58
Short interest%
1.54
SBC / revenue%
2.75
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
25–30
$1 testx
0.2
Incr. ROIC%
7